Advicenne S.A. (ALDVI.PA)
Paris · EUR · Healthcare · Biotechnology
€0.692 (+9.84%) as of
Key statistics
- Market cap
- 10.54M
- P/E (TTM)
- 9.89
- Forward P/E
- -1.57
- EPS (TTM)
- 0.0700
- Dividend yield
- 0.00%
- 52-week range
- 0.6090 – 2.3500
- Beta
- 0.97
- Revenue (TTM)
- 10.74M
- Profit margin
- 0.40%
- Volume
- 18.84k
About Advicenne S.A.
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Paris, France
- Employees
- 11
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.